COSM Cosmos Health Inc.

Cosmos Health Inc.

Other Pharmaceuticals

Health Care

Cosmos Holdings Inc. operates as a vertically integrated pharmaceutical company. It offers proprietary line of branded and generic pharmaceuticals, nutraceuticals, over-the-counter (OTC) medications, health care, baby products, medical devices, and other products through its distribution channels and e-commerce market place. The company identifies, acquires, develops, and commercializes products that enhance patients' lives and outcomes, as well as has distribution centers in Greece, and the United Kingdom; and warehousing facility. It serves wholesale pharmaceutical distributors and independent retail pharmacies. The company was formerly known as Prime Estates and Developments, Inc. and changed its name to Cosmos Holdings Inc. in November 2013. Cosmos Holdings Inc. was incorporated in 2009 and is based in Chicago, Illinois.

IPO Year:

Exchange: NASDAQ

Website: https://www.cosmosholdingsinc.com

Recent Analyst Ratings for Cosmos Health Inc.

Date	Price Target	Rating	Analyst

See more ratings

Cosmos Health Inc. Press Releases

Fastest customizable press release news feed in the world

RETRANSMISSION – Cosmos Health Reports Q1 2025 Results: Adjusted Profitability Achieved as Gross Profit Rises 54% to $2.05M; Operating Cash Burn Down 95%, or $3.2M, to $0.19M; Approaching Cash Flow Breakeven
CHICAGO, May 15, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Highlights Income Statement Cosmos Health delivered solid results in Q1 2025, highlighted by a significant increase in gross profit and positive performance on both an Adjusted EBITDA and Adjusted Net Income basis, reflecting a
5/15/25 2:30:35 PM ET
$COSM
Other Pharmaceuticals
Health Care
Cosmos Health Secures Follow-Up Order from Pharmalink for 80,000 Sky Premium Life Units in the UAE; Initial 130,000-unit Order Sold Out, Advancing 5-Year Goal of Over 3 Million Units
CHICAGO, May 07, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has received an additional purchase order for 80,000 units from Pharmalink for its Sky Premium Life products in the United Arab Emirates (UAE). This latest order, pursuant to the exclusive distribution agreement with Pharmalink, follows the successful sell-out of the initial 130,000-unit purchase and supports the Comp
5/7/25 2:30:10 PM ET
$COSM
Other Pharmaceuticals
Health Care
Cosmos Health Receives Additional 180-Day Compliance Period from Nasdaq
CHICAGO, May 06, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has received formal notice from the Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company is eligible for an additional 180 calendar day period, through November 3, 2025, to regain compliance with the Nasdaq's minimum bid price requirement. As previously disclosed, on November 6, 2024, the Company was not
5/6/25 1:40:33 PM ET
$COSM
Other Pharmaceuticals
Health Care
Cosmos Health CEO Greg Siokas Acquires 1,466,764 Shares Valued at $526,000 Over the Past Week; 2,777,469 Shares Acquired Over the Past Five Months for $1,325,000
CHICAGO, April 30, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its CEO, Greg Siokas, has increased his stake in the Company by acquiring a total of 1,466,764 common shares, valued at $526,000, across five transactions between April 21, 2025, and April 24, 2025. As a result of these transactions, Mr. Siokas now beneficially owns 5,582,066 common shares in Cosmos Health. Greg S
4/30/25 12:50:09 PM ET
$COSM
Other Pharmaceuticals
Health Care
Cosmos Health Reports Full-Year 2024 Results: Revenue Increases 2% to $54.43 Million While Operating Expenses Decline 24.2% to $19.86 Million
CHICAGO, April 16, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, today reported financial results for the full year ended December 31, 2024. Full Year 2024 Financial Highlights Income Statement: FY 2024 performance was marked by revenue growth, an increase in R&D investments, and a substantial reduction in operating expenses, while bottom-line results were impacted by the absence of non-recurring gain
4/16/25 12:45:15 PM ET
$COSM
Other Pharmaceuticals
Health Care
Cosmos Health Further Expands Facility Upgrades Program at Cana Laboratories and Signs 5-Year Contract Manufacturing Agreement with Pharmex for 1.5 Million Bottles of the Antiseptic Drug AMBITASOL 1L
CHICAGO, April 09, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its wholly owned subsidiary, Cana Laboratories ("Cana"), has completed the latest upgrades to its manufacturing capabilities and capacity, and has secured a long-term, five-year contract manufacturing agreement with Pharmex S.A. ("Pharmex") for the annual production of 300,000 bottles of the antiseptic drug AMBITASOL 1L
4/9/25 1:40:47 PM ET
$COSM
Other Pharmaceuticals
Health Care
Cosmos Health Launches Sky Premium Life in Albania through Partnership with Pharma Cell; Secures Initial $300,000 Order
CHICAGO, April 08, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today the launch of its Sky Premium Life food supplements brand in Albania, in partnership with Pharma Cell, a leading consumer health and medical supplement company that will serve as the distributor in the country. Cosmos Health has secured an initial annual order worth $300,000 and anticipates further scaling its collaboration
4/8/25 10:45:34 AM ET
$COSM
Other Pharmaceuticals
Health Care
Cosmos Health CEO Greg Siokas Acquires a Total of 647,809 Shares Valued at $425,000 Over the Past 32 Days
CHICAGO, IL / ACCESS Newswire / January 21, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its CEO, Greg Siokas, has increased his stake in the Company by acquiring a total of 647,809 common shares, valued at $425,000, across six transactions between December 20, 2024, and January 17, 2025.As a result of these transactions, Mr. Siokas now beneficially owns 4,164,789 common shares in Cosmos Health.Greg Si
1/21/25 3:00:00 PM ET
$COSM
Other Pharmaceuticals
Health Care
Cosmos Health Secures Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Greece and Cyprus, with Additional Rights in Select European and GCC Countries
CHICAGO, IL / ACCESSWIRE / January 13, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has entered into a distribution agreement with Virax Biolabs Group Limited (NASDAQ:VRAX) ("Virax") to distribute Virax-branded Avian Influenza Virus ("AIV") Real-Time PCR Kits across various major European markets and certain Gulf Cooperation Council (GCC) countries.Specifically, Cosmos Health gains exclusive rights t
1/13/25 9:20:00 AM ET
$COSM
$VRAX
Other Pharmaceuticals
Health Care
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Cosmos Health Strengthens R&D Leadership and Innovation with the Appointment of Professor Dimitrios Trafalis, MD, as Head of Oncology
CHICAGO, IL / ACCESSWIRE / December 26, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today the appointment of Professor Dimitrios Trafalis, MD, as Head of Oncology at the Company's Research and Development division.Professor Trafalis currently serves as a Professor of Pharmacology and Clinical Pharmacology at the Faculty of Medicine, National and Kapodistrian University of Athens.He is a medical specialist in onc
12/26/24 1:30:00 PM ET
$COSM
Other Pharmaceuticals
Health Care

Cosmos Health Inc. Leadership Updates

Live Leadership Updates

Cosmos Health Reports Full-Year 2024 Results: Revenue Increases 2% to $54.43 Million While Operating Expenses Decline 24.2% to $19.86 Million
CHICAGO, April 16, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, today reported financial results for the full year ended December 31, 2024. Full Year 2024 Financial Highlights Income Statement: FY 2024 performance was marked by revenue growth, an increase in R&D investments, and a substantial reduction in operating expenses, while bottom-line results were impacted by the absence of non-recurring gain
4/16/25 12:45:15 PM ET
$COSM
Other Pharmaceuticals
Health Care
Cosmos Health Strengthens R&D Leadership and Innovation with the Appointment of Professor Dimitrios Trafalis, MD, as Head of Oncology
CHICAGO, IL / ACCESSWIRE / December 26, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today the appointment of Professor Dimitrios Trafalis, MD, as Head of Oncology at the Company's Research and Development division.Professor Trafalis currently serves as a Professor of Pharmacology and Clinical Pharmacology at the Faculty of Medicine, National and Kapodistrian University of Athens.He is a medical specialist in onc
12/26/24 1:30:00 PM ET
$COSM
Other Pharmaceuticals
Health Care
Cosmos Health Reports Q3 2023 Results; Revenue Increased 7% YoY, Total Assets Reached Record $71.5M with Stockholders' Equity of $44.2M or $3.4/Share
THESSALONIKI, GREECE / ACCESSWIRE / November 21, 2023 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, today provided a business update and reported financial results for the third quarter and nine months ended September 30, 2023.Third Quarter 2023 Financial HighlightsRevenues increased to $12.8 million from $12.0 million in Q3 2022, largely due to increased sales attributable to the logistics distribution business, which expanded
11/21/23 9:00:00 AM ET
$COSM
Other Pharmaceuticals
Health Care
Cosmos Health Appoints Big 4 Accounting Firm KPMG as Auditor
CHICAGO, IL / ACCESSWIRE / August 8, 2023 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, announced today the engagement of KPMG Certified Auditors S.A. ("KPMG") as the Company's independent registered public accounting firm, effective August 7, 2023. KPMG replaces the Company's former auditor, Armanino LLP.The appointment of KPMG was made by the Cosmos Health Board of Directors at the recommendation of its Audit Committee. The decision to change auditors was not the result of any disagreement between the Company
8/8/23 9:20:00 AM ET
$COSM
Other Pharmaceuticals
Health Care
Cosmos Health Announces the Appointment of Nikos Bardakis, an Experienced Executive in the Pharmaceutical Industry, as Chief Operating Officer
CHICAGO, IL / ACCESSWIRE / February 1, 2023 / Cosmos Health Inc. ("the Company") (NASDAQ:COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, is pleased to announce the appointment of Nikos Bardakis, who comes with over two decades of international branded pharmaceutical sector experience, as the Chief Operating Officer (COO).As the Chief Operating Officer at Cosmos Health, Mr. Bardakis' objective will be to bring new capabilities and processes into the organization for optimizing operational excellence towards global commercial expansion of Cosmos' premium products. In addition, M
2/1/23 11:00:00 AM ET
$COSM
Other Pharmaceuticals
Health Care
Cosmos Holdings Appoints Dr. Manfred Ziegler to its Advisory Board
CHICAGO, IL / ACCESSWIRE / July 22 , 2022 / Cosmos Holdings, Inc. ("the Company") (NASDAQ:COSM), an international pharmaceutical company with a proprietary line of nutraceuticals and distributor of branded and generic pharmaceuticals, nutraceuticals, OTC medications and medical devices, today announced that it has appointed finance veteran Dr. Manfred Ziegler to the Company's Advisory Board.Dr. Ziegler brings over 30 years of executive management, financial, and operational experience, as well as extensive expertise in mergers and acquisitions, with a particular focus on high-growth public and private companies. Notably, Dr. Manfred Ziegler served as Chief Executive Officer of CC Pharma, a l
7/22/22 9:15:00 AM ET
$COSM
$APHA
Other Pharmaceuticals
Health Care
Specialty Chemicals
Consumer Durables
Cosmos Holdings Appoints Finance Veteran Dr. Anastasios Aslidis to the Board of Directors and as a Member of the Board's Audit Committee
CHICAGO, IL / ACCESSWIRE / May 3, 2022 / Cosmos Holdings, Inc. ("the Company") (NASDAQ:COSM), an international pharmaceutical company with a proprietary line of nutraceuticals and distributor of branded and generic pharmaceuticals, nutraceuticals, OTC medications and medical devices, today announced it has appointed finance veteran Dr. Anastasios Aslidis to the Board of Directors and as a member of the Board's audit committee.Dr. Anastasios Aslidis currently serves as the Chief Financial Officer and Treasurer, as well as a member of the Board of Directors of EuroDry (EDRY) since 2018. He is Chief Financial Officer, Treasurer and a member of the Board of Directors of Euroseas (NASDAQ:ESEA) si
5/3/22 9:15:00 AM ET
$COSM
$ESEA
Other Pharmaceuticals
Health Care
Marine Transportation
Consumer Discretionary

Cosmos Health Inc. Financials

Live finance-specific insights

Cosmos Health CEO Greg Siokas Acquires 1,466,764 Shares Valued at $526,000 Over the Past Week; 2,777,469 Shares Acquired Over the Past Five Months for $1,325,000
CHICAGO, April 30, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its CEO, Greg Siokas, has increased his stake in the Company by acquiring a total of 1,466,764 common shares, valued at $526,000, across five transactions between April 21, 2025, and April 24, 2025. As a result of these transactions, Mr. Siokas now beneficially owns 5,582,066 common shares in Cosmos Health. Greg S
4/30/25 12:50:09 PM ET
$COSM
Other Pharmaceuticals
Health Care
Cosmos Health CEO Greg Siokas Acquires a Total of 647,809 Shares Valued at $425,000 Over the Past 32 Days
CHICAGO, IL / ACCESS Newswire / January 21, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its CEO, Greg Siokas, has increased his stake in the Company by acquiring a total of 647,809 common shares, valued at $425,000, across six transactions between December 20, 2024, and January 17, 2025.As a result of these transactions, Mr. Siokas now beneficially owns 4,164,789 common shares in Cosmos Health.Greg Si
1/21/25 3:00:00 PM ET
$COSM
Other Pharmaceuticals
Health Care
Cosmos Health Issues Letter to Shareholders
CHICAGO, IL / ACCESSWIRE / November 12, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its Chief Executive Officer, Greg Siokas, has issued the following letter to the Company's shareholders.Dear Cosmos Health Shareholders,It has been just over a year since my previous shareholder letter, and I would like to express my sincere gratitude for your continued support. We have achieved many positive milestone
11/12/24 12:01:41 PM ET
$COSM
Other Pharmaceuticals
Health Care
Cosmos Health Commences Development of Cloudscreen 2.0, the New Iteration of its Next Generation AI Drug Repurposing Platform
CHICAGO, IL / ACCESSWIRE / March 21, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today the initiation of the development of Cloudscreen 2.0, the new iteration of its groundbreaking Artificial Intelligence (AI) drug repurposing platform.As previously announced, on January 23, 2024, Cosmos Health completed the acquisition of Cloudscreen. Building on the success of its predecessor, Cloudscreen 2.0 represents a sign
3/21/24 9:45:00 AM ET
$COSM
Other Pharmaceuticals
Health Care
Cosmos Health Completes Acquisition of Cloudscreen, a Cutting-Edge AI Platform; Enters Lucrative $25Bn+ Global Drug Repurposing Market
CHICAGO, IL / ACCESSWIRE / January 23, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has successfully completed the acquisition of Cloudscreen®, a cutting-edge Artificial Intelligence (AI) powered platform. The acquisition is pursuant to the purchase agreement announced on October 11, 2023.Cloudscreen is a multimodal platform specialized in drug repurposing, a process that involves uncovering new tar
1/23/24 1:05:00 PM ET
$COSM
Other Pharmaceuticals
Health Care
Cosmos Health Bolsters Presence in $400Bn+ Global Generic Drugs Market with $3.5M Acquisition of 10-Drug Portfolio
CHICAGO, IL / ACCESSWIRE / January 18, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has successfully completed the acquisition of the licenses and rights of a comprehensive portfolio of 10 generic drugs from a related party for €3.2 million, or approximately $3.5 million at today's exchange rate.This strategic acquisition significantly enhances Cosmos Health's pharmaceutical portfolio. The selected d
1/18/24 9:25:00 AM ET
$COSM
Other Pharmaceuticals
Health Care
Cosmos Health Reports First Quarter 2023 Financial Results; Delivers Positive Adjusted EBITDA and Significant Increase in Adjusted Net Income
CHICAGO, IL / ACCESSWIRE / May 17, 2023 / Cosmos Health Inc. ("Cosmos Health" or "the Company") (NASDAQ:COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, today provided a business update and reported financial results for the first quarter ended March 31, 2023.First Quarter 2023 Financial HighlightsRevenues amounted to $12.35 million, compared to $13.07 million in Q1 2022. When considered on a constant currency basis, using quarterly average Q1 2022 exchange rates, revenues were virtually flat at $13.03 million, highlighting the stability of our platform.Adjusted EBITDA was $0.4
5/17/23 8:00:00 AM ET
$COSM
Other Pharmaceuticals
Health Care
Cosmos Health Advances Its Strategic Plan; Acquires Distressed Property Housing Operations of CosmoFarm, Expected to Generate Substantial Value for Shareholders
CHICAGO, IL / ACCESSWIRE / May 3, 2023 / Cosmos Health Inc. ("Cosmos Health" or "the Company") (NASDAQ:COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, today announced that is has acquired the entire property which houses the operations of its wholly owned subsidiary CosmoFarm Pharmaceuticals ("CosmoFarm"), a fully licensed pharmaceutical wholesale company operating in the western part of Athens, Greece.The CosmoFarm property, pictured below, comprises an entire 3-story building, 2,700 square meters (or approximately 29,063 square feet) in size. The purchase price was €966,000
5/3/23 1:35:00 PM ET
$COSM
Other Pharmaceuticals
Health Care
Cosmos Health Inc. Enters U.S. Telehealth Space with Successful Acquisition of ZipDoctor, Inc.
CHICAGO, IL / ACCESSWIRE / April 3, 2023 / Cosmos Health Inc. ("Cosmos Health" or "the Company") (NASDAQ:COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, announced today that it has successfully completed the acquisition of ZipDoctor, Inc. ("ZipDoctor") from American International Holdings Corp (AMIH). The financial terms of the acquisition were not disclosed.ZipDoctor is a direct-to-consumer subscription-based telemedicine platform, that expects to provide its customers affordable, unlimited, 24/7 access to board certified physicians and licensed mental and behavioural health
4/3/23 11:55:00 AM ET
$COSM
Other Pharmaceuticals
Health Care
Cosmos Health Announces Application for Dual Listing on Upstream
CHICAGO, IL / ACCESSWIRE / February 2, 2023 / Cosmos Health Inc. (NASDAQ:COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, today announced that is has begun the application process to dual list its shares on Upstream, the trading app for digital securities and NFTs powered by Horizon Fintex ("Horizon") and MERJ Exchange Limited ("MERJ").The planned dual listing on Upstream is designed to provide Cosmos Health the opportunity to access a global, digital-first investor base that can trade using USDC digital currency along with credit, debit, PayPal, and USD, increasing liquidity a
2/2/23 1:50:00 PM ET
$COSM
Other Pharmaceuticals
Health Care

Cosmos Health Inc.

Recent Analyst Ratings for Cosmos Health Inc.

Cosmos Health Inc.

Recent Analyst Ratings for Cosmos Health Inc.

Cosmos Health Inc. SEC Filings

SEC Form 10-Q filed by Cosmos Health Inc.

Cosmos Health Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

SEC Form 10-K filed by Cosmos Health Inc.

SEC Form NT 10-K filed by Cosmos Health Inc.

Cosmos Health Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

Amendment: SEC Form S-1/A filed by Cosmos Health Inc.

Cosmos Health Inc. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Financial Statements and Exhibits

Cosmos Health Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

Amendment: SEC Form S-1/A filed by Cosmos Health Inc.

Amendment: SEC Form S-1/A filed by Cosmos Health Inc.

Cosmos Health Inc. Press Releases

Fastest customizable press release news feed in the world

RETRANSMISSION – Cosmos Health Reports Q1 2025 Results: Adjusted Profitability Achieved as Gross Profit Rises 54% to $2.05M; Operating Cash Burn Down 95%, or $3.2M, to $0.19M; Approaching Cash Flow Breakeven

Cosmos Health Secures Follow-Up Order from Pharmalink for 80,000 Sky Premium Life Units in the UAE; Initial 130,000-unit Order Sold Out, Advancing 5-Year Goal of Over 3 Million Units

Cosmos Health Receives Additional 180-Day Compliance Period from Nasdaq

Cosmos Health CEO Greg Siokas Acquires 1,466,764 Shares Valued at $526,000 Over the Past Week; 2,777,469 Shares Acquired Over the Past Five Months for $1,325,000

Cosmos Health Reports Full-Year 2024 Results: Revenue Increases 2% to $54.43 Million While Operating Expenses Decline 24.2% to $19.86 Million

Cosmos Health Further Expands Facility Upgrades Program at Cana Laboratories and Signs 5-Year Contract Manufacturing Agreement with Pharmex for 1.5 Million Bottles of the Antiseptic Drug AMBITASOL 1L

Cosmos Health Launches Sky Premium Life in Albania through Partnership with Pharma Cell; Secures Initial $300,000 Order

Cosmos Health CEO Greg Siokas Acquires a Total of 647,809 Shares Valued at $425,000 Over the Past 32 Days

Cosmos Health Secures Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Greece and Cyprus, with Additional Rights in Select European and GCC Countries

Cosmos Health Strengthens R&D Leadership and Innovation with the Appointment of Professor Dimitrios Trafalis, MD, as Head of Oncology

Cosmos Health Inc. Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Executive Officer Siokas Grigorios bought $65,961 worth of shares (147,563 units at $0.45), increasing direct ownership by 3% to 5,808,883 units (SEC Form 4)

Chief Executive Officer Siokas Grigorios bought $34,000 worth of shares (79,254 units at $0.43), increasing direct ownership by 1% to 5,661,320 units (SEC Form 4)

Chief Executive Officer Siokas Grigorios bought $102,000 worth of shares (254,618 units at $0.40), increasing direct ownership by 5% to 5,582,066 units (SEC Form 4)

Chief Executive Officer Siokas Grigorios bought $71,000 worth of shares (177,234 units at $0.40), increasing direct ownership by 3% to 5,327,448 units (SEC Form 4)

Chief Executive Officer Siokas Grigorios bought $82,000 worth of shares (205,000 units at $0.40), increasing direct ownership by 4% to 5,150,214 units (SEC Form 4)

Chief Executive Officer Siokas Grigorios bought $63,000 worth of shares (175,000 units at $0.36), increasing direct ownership by 4% to 4,945,214 units (SEC Form 4)

Chief Executive Officer Siokas Grigorios bought $208,000 worth of shares (654,912 units at $0.32), increasing direct ownership by 16% to 4,770,214 units (SEC Form 4)

New insider Demetriades Demetrios G. claimed ownership of 20,000 shares (SEC Form 3)

Chief Executive Officer Siokas Grigorios bought $45,000 worth of shares (85,714 units at $0.53), increasing direct ownership by 2% to 4,115,302 units (SEC Form 4)

Chief Executive Officer Siokas Grigorios bought $65,000 worth of shares (132,572 units at $0.49), increasing direct ownership by 3% to 4,029,588 units (SEC Form 4)

Cosmos Health Inc. Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Chief Executive Officer Siokas Grigorios bought $65,961 worth of shares (147,563 units at $0.45), increasing direct ownership by 3% to 5,808,883 units (SEC Form 4)

Chief Executive Officer Siokas Grigorios bought $34,000 worth of shares (79,254 units at $0.43), increasing direct ownership by 1% to 5,661,320 units (SEC Form 4)

Chief Executive Officer Siokas Grigorios bought $102,000 worth of shares (254,618 units at $0.40), increasing direct ownership by 5% to 5,582,066 units (SEC Form 4)

Chief Executive Officer Siokas Grigorios bought $71,000 worth of shares (177,234 units at $0.40), increasing direct ownership by 3% to 5,327,448 units (SEC Form 4)

Chief Executive Officer Siokas Grigorios bought $82,000 worth of shares (205,000 units at $0.40), increasing direct ownership by 4% to 5,150,214 units (SEC Form 4)

Chief Executive Officer Siokas Grigorios bought $63,000 worth of shares (175,000 units at $0.36), increasing direct ownership by 4% to 4,945,214 units (SEC Form 4)

Chief Executive Officer Siokas Grigorios bought $208,000 worth of shares (654,912 units at $0.32), increasing direct ownership by 16% to 4,770,214 units (SEC Form 4)

Chief Executive Officer Siokas Grigorios bought $45,000 worth of shares (85,714 units at $0.53), increasing direct ownership by 2% to 4,115,302 units (SEC Form 4)

Chief Executive Officer Siokas Grigorios bought $65,000 worth of shares (132,572 units at $0.49), increasing direct ownership by 3% to 4,029,588 units (SEC Form 4)

Chief Executive Officer Siokas Grigorios bought $200,000 worth of shares (354,296 units at $0.56), increasing direct ownership by 10% to 3,897,016 units (SEC Form 4)

Cosmos Health Inc. Leadership Updates

Live Leadership Updates

Cosmos Health Reports Full-Year 2024 Results: Revenue Increases 2% to $54.43 Million While Operating Expenses Decline 24.2% to $19.86 Million

Cosmos Health Strengthens R&D Leadership and Innovation with the Appointment of Professor Dimitrios Trafalis, MD, as Head of Oncology

Cosmos Health Reports Q3 2023 Results; Revenue Increased 7% YoY, Total Assets Reached Record $71.5M with Stockholders' Equity of $44.2M or $3.4/Share

Cosmos Health Appoints Big 4 Accounting Firm KPMG as Auditor

Cosmos Health Announces the Appointment of Nikos Bardakis, an Experienced Executive in the Pharmaceutical Industry, as Chief Operating Officer

Cosmos Holdings Appoints Dr. Manfred Ziegler to its Advisory Board

Cosmos Holdings Appoints Finance Veteran Dr. Anastasios Aslidis to the Board of Directors and as a Member of the Board's Audit Committee

Cosmos Health Inc. Financials

Live finance-specific insights

Cosmos Health CEO Greg Siokas Acquires 1,466,764 Shares Valued at $526,000 Over the Past Week; 2,777,469 Shares Acquired Over the Past Five Months for $1,325,000

Cosmos Health CEO Greg Siokas Acquires a Total of 647,809 Shares Valued at $425,000 Over the Past 32 Days

Cosmos Health Issues Letter to Shareholders

Cosmos Health Commences Development of Cloudscreen 2.0, the New Iteration of its Next Generation AI Drug Repurposing Platform

Cosmos Health Completes Acquisition of Cloudscreen, a Cutting-Edge AI Platform; Enters Lucrative $25Bn+ Global Drug Repurposing Market

Cosmos Health Bolsters Presence in $400Bn+ Global Generic Drugs Market with $3.5M Acquisition of 10-Drug Portfolio

Cosmos Health Reports First Quarter 2023 Financial Results; Delivers Positive Adjusted EBITDA and Significant Increase in Adjusted Net Income

Cosmos Health Advances Its Strategic Plan; Acquires Distressed Property Housing Operations of CosmoFarm, Expected to Generate Substantial Value for Shareholders

Cosmos Health Inc. Enters U.S. Telehealth Space with Successful Acquisition of ZipDoctor, Inc.

Cosmos Health Announces Application for Dual Listing on Upstream

Cosmos Health Inc. Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Cosmos Health Inc.

SEC Form SC 13G filed by Cosmos Health Inc.

SEC Form SC 13D/A filed by Cosmos Health Inc. (Amendment)

SEC Form SC 13D/A filed by Cosmos Holdings Inc. (Amendment)

SEC Form SC 13D filed by Cosmos Holdings Inc.

SEC Form SC 13D/A filed by Cosmos Holdings Inc. (Amendment)